Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fangyi Zhao

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
BMC Psychiatry|December 26, 2014
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaAnnCatherine M Downing, Bruce J Kinon, Brian A Millen, et al.
Rheumatology and Therapy|June 30, 2019
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing SpondylitisPhilip Mease, Jessica A Walsh, Xenofon Baraliakos, et al.
American Journal of Clinical Dermatology|May 17, 2023
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical TrialsLinda Stein Gold, Diamant Thaçi, Jacob P Thyssen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2018
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor InhibitorsAtul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, et al.
Annals of the Rheumatic Diseases|April 16, 2015
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind studyJosef S Smolen, Michael E Weinblatt, Désirée van der Heijde, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Nature Microbiology|September 11, 2024
Blockade of endothelin receptors mitigates SARS-CoV-2-induced osteoarthritisMan Ting Au, Junguo Ni, Kaiming Tang, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
BMC Psychiatry|December 26, 2014
A Double-Blind, Placebo-Controlled Comparator Study of LY2140023 monohydrate in patients with schizophreniaAnnCatherine M Downing, Bruce J Kinon, Brian A Millen, et al.
Rheumatology and Therapy|June 30, 2019
Translating Improvements with Ixekizumab in Clinical Trial Outcomes into Clinical Practice: ASAS40, Pain, Fatigue, and Sleep in Ankylosing SpondylitisPhilip Mease, Jessica A Walsh, Xenofon Baraliakos, et al.
American Journal of Clinical Dermatology|May 17, 2023
Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical TrialsLinda Stein Gold, Diamant Thaçi, Jacob P Thyssen, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|October 22, 2018
Efficacy and Safety of Ixekizumab in the Treatment of Radiographic Axial Spondyloarthritis: Sixteen-Week Results From a Phase III Randomized, Double-Blind, Placebo-Controlled Trial in Patients With Prior Inadequate Response to or Intolerance of Tumor Necrosis Factor InhibitorsAtul Deodhar, Denis Poddubnyy, Cesar Pacheco-Tena, et al.
Annals of the Rheumatic Diseases|April 16, 2015
Efficacy and safety of tabalumab, an anti-B-cell-activating factor monoclonal antibody, in patients with rheumatoid arthritis who had an inadequate response to methotrexate therapy: results from a phase III multicentre, randomised, double-blind studyJosef S Smolen, Michael E Weinblatt, Désirée van der Heijde, et al.
Lancet (London, England)|October 27, 2018
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trialDésirée van der Heijde, James Cheng-Chung Wei, Maxime Dougados, et al.
Annals of the Rheumatic Diseases|November 6, 2019
Efficacy and safety of ixekizumab through 52 weeks in two phase 3, randomised, controlled clinical trials in patients with active radiographic axial spondyloarthritis (COAST-V and COAST-W)Maxime Dougados, James Cheng-Chung Wei, Robert Landewé, et al.
Nature Microbiology|September 11, 2024
Blockade of endothelin receptors mitigates SARS-CoV-2-induced osteoarthritisMan Ting Au, Junguo Ni, Kaiming Tang, et al.
The New England Journal of Medicine|June 15, 2016
Phase 3 Trials of Ixekizumab in Moderate-to-Severe Plaque PsoriasisKenneth B Gordon, Andrew Blauvelt, Kim A Papp, et al.
Pageof 5